Deal type
- Management buyout
ChargePoint manufactures and delivers enhanced sterile & contained process solutions to companies across Europe, Asia and North America.
Its patented technology is used by the world’s top 50 global pharmaceutical manufacturers. It helps transfer highly potent and sterile powders reliably and safely within advanced manufacturing facilities.
Turning on the growth tap
LDC first backed ChargePoint CEO Chris Eccles in 2017, providing investment to help the business to capitalise on growing international demand for its products.
The partnership also gave Chris the financial firepower to increase investment in new product development, allowing ChargePoint to expand its market share by manufacturing complementary, single use products alongside continuing improvement of its core range.
The continued support we received from LDC has been instrumental in allowing us to maintain growth, champion R&D and realise our global expansion ambitions.”Chris Eccles, CEO
ChargePoint
During its four-year partnership with LDC, ChargePoint successfully launched a series of new solutions including its VERIFi™ platform, a smart monitoring technology that provides information an equipment usage allowing preventative maintenance, and AseptiSafe® Bio, a specialist valve for customers working with toxic and sensitive substances. The business increased revenues approximately 30 per cent. It has also secured several new contract wins in Canada, which strengthened its presence further in the North American region.
LDC exited its investment in ChargePoint to US private equity firm Arcline Investment Management in February 2021.
We partnered with LDC to help us expand our product range and accelerate our international expansions plans. Today, we’re a growing international business that serves most of the world’s leading pharmaceutical businesses.”Chris Eccles, CEO
ChargePoint
Awards
Deal of the Year
Insider North West Dealmakers
